Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis

Hu, Yong; Sun, Jiazhong; Dai, Zhijiang; Deng, Huaxin; Li, Xin; Huang, Qi; Wu, Yue; Sun, Li; Xu, Yancheng

doi:10.1016/j.jcv.2020.104371

Cited by 576 publications

(584 citation statements)

References 42 publications

Supporting

Mentioning

496

Contrasting

Unclassified

Order By: Relevance

“…However, Zhang et al found no signi cant correlation between the rate of severe events and the stage of cancer. (13) In terms of life threatening complications, the rate of ARDS in our patients was higher than in the metaanalysis reported by Yong et al (15) We found that the mortality rate was signi cantly higher among the patients with active cancer who had undergone cytotoxic chemotherapy less than 14 days prior to being admitted due to COVID-19, in comparison with the patients who did not have an active cancer and were not on recent cytotoxic therapies. This nding is similar to the report by Zhang et al(13) However, Kuderer et al (14) found no signi cant difference between undergoing cytotoxic chemotherapy within 30 days prior to COVID-19 diagnosis and its consequential mortality rate.…”

Section: Discussioncontrasting

confidence: 64%

COVID-19 and Cancer: A Comparative Case Series

Mousavi

Rostami

Kiumarsi

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundCancer patients, with an incidence of more than 18 million new cases per year, may constitute a significant portion of the COVID-19 infected population. In the pandemic situation, these patients are considered highly vulnerable to infectious complications due to their immunocompromised state.Material & MethodsIn this retrospective case series, the documents of solid cancer patients infected by SARS-CoV-2, hospitalized in Shariati hospital (a tertiary care referral center designated for COVID-19 patients, affiliated by Tehran University of Medical Sciences) between 20 February and 20 April 2020, were evaluated. The diagnosis of COVID-19 was based on a positive real-time fluorescence reverse transcription-polymerase chain reaction (RT-PCR) for SARS-CoV-2 nucleic acids from nasal and/or pharyngeal specimens and/or features of chest CT scan highly suggestive for SARS-CoV-2.ResultsAmong 33 patients with solid cancer, 11 patients had a positive RT-PCR for SARS-CoV-2 and 22 patients had highly suggestive chest CT scan findings in favor of SARS-CoV-2 but negative RT-PCR . The mean age of the patients was 63.9 years, and 54.5% of the patients were males. Age and sex of the patients did not correlate with mortality. There was no difference in COVID-19 symptoms, lymphocytopenia, thrombocytopenia between survived and un-survived cancer patients. However, LDH level was significantly higher (7170±2077 vs. 932.3±324.7, P-value=0.016) and also serum albumin was significantly lower in un-survived group (3.6±0.5 vs. 2.9±0.6 p-value=0.03). Among 16 patients with stage IV cancer, thirteen patients died, which was significantly higher compared to stage I-III cancer patients (81.3% vs. 18.8% P-value= <0.001). In terms of developing complications, sepsis, invasive ventilation and mortality was significantly higher in patients who received cytotoxic chemotherapy within the last 14 days. There was no significant difference between the two groups of positive and negative SARS-CoV-2 RT-PCR regarding their sex, age, cancer type, mean Hemoglobin concentration, Platelet count, lymphocyte count, serum albumin level, ESR and CRP titer or other laboratory findings and also in terms of clinical symptoms and coexisting.ConclusionIn this study, we showed that the mortality rate among cancer patients affected by COVID-19 was higher than general population and this rate has a significant correlation with factors such as the stage of the disease, the type of cancer, the activity of cancer and finally receiving cytotoxic chemotherapy within 14 days before diagnosis of COVID-19. We also showed that the outcome of cancer patients with positive RT-PCR for COVID-19 similar to those with negative RT-PCR with highly suggestive chest CT scan findings.

show abstract

Section: Discussioncontrasting

confidence: 64%

COVID-19 and Cancer: A Comparative Case Series

Mousavi

Rostami

Kiumarsi

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Gastrointestinal symptoms were also present with diarrhoea being the most common one. As compared to the other studies (33,34,37,43,44), fever and cough had similar WPP, however, dyspnoea was found to be more prevalent in older patients as compared to the younger ones. Similarly, though diarrhoea has been noted as the most common gastrointestinal symptom in other studies (33,43) too, it has comparatively higher WPP in older population.…”

Section: Discussionsupporting

confidence: 37%

“…A marginal difference was observed when the subgroup analysis was done for patients in China (15%) and outside China (11%), which was not statistically signi cant. The published meta-analysis on COVID-19 has reported its mortality ranging from 3.1-5.5% (32)(33)(34)37). Hence, the fatality rate in our study is signi cantly higher, re ecting the poor resilience of older patients to COVID-19.…”

Section: Discussionmentioning

confidence: 51%

See 1 more Smart Citation

Clinical Features and Outcomes of COVID-19 in Older Adults: A Systematic Review and Meta-Analysis

Singhal

Kumar

Singh

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract Background Few studies have focused on exploring the clinical characteristics and outcomes of COVID-19 in older patients. We conducted this systematic review and meta-analysis to have a better understanding of the clinical characteristics of older COVID-19 patients.Methods A systematic search of PubMed and Scopus was performed from December 2019 to May 3rd, 2020. Observational studies including older adults (age ≥60 years) with COVID-19 infection and reporting clinical characteristics or outcome were included. Primary outcome was assessing weighted pooled prevalence (WPP) of severity and outcomes. Secondary outcomes were clinical features including comorbidities and need of respiratory support.Result 46 studies with 13,624 older patients were included. Severe infection was seen in 51% (95% CI– 36-65%, I2- 95%) patients while 22% (95% CI– 16-28%, I2- 88%) were critically ill. Overall, 11% (95% CI– 5-21%, I2- 98%) patients died. The common comorbidities were hypertension (48%, 95% CI– 36-60% I2- 92%), diabetes mellitus (22%, 95% CI– 13-32%, I2- 86%) and cardiovascular disease (19%, 95% CI – 11-28%, I2- 85%). Common symptoms were fever (83%, 95% CI– 66-97%, I2-91%), cough (60%, 95% CI– 50-70%, I2- 71%) and dyspnoea (42%, 95% CI– 19-67%, I2- 94%). Overall, 84% (95% CI– 60-100%, I2- 81%) required oxygen support and 21% (95% CI– 0-49%, I2- 91%) required mechanical ventilation. Majority of studies had medium to high risk of bias and overall quality of evidence was low for all outcomes.Conclusion Approximately half of older patients with COVID-19 have severe infection, one in five are critically ill and one in ten die. More high quality evidence is needed to study outcomes in this vulnerable patient population and factors affecting these outcomes.

show abstract

“…As of April 22, 2020, a total of 2,471,136 laboratory-confirmed cases were reported worldwide, with a mortality rate of 6.8% [4]. Previous studies have shown that comorbidities in patients with COVID-19 are associated with poor prognosis, including hypertension, diabetes, chronic obstructive pulmonary disease (COPD), cardiovascular disease, and cerebrovascular disease [5][6][7].…”

Section: Introductionmentioning

confidence: 99%

Cancer is associated with the severity and mortality of patients with COVID-19: a systematic review and meta-analysis

Gao

Liu

Shi

et al. 2020

Preprint

View full text Add to dashboard Cite

word count: 249. AbstractBackground: Cancer patients are considered a highly vulnerable population in the COVID-19 epidemic, but the relationship between cancer and the severity and mortality of patients with COVID-19 remains unclear. This study aimed to explore the prevalence of cancer in patients with COVID-19 and to examine whether cancer patients with COVID-19 may be at an increased risk of severe illness and mortality. Methods:A comprehensive electronic search in seven databases was performed, to identified studies reporting the prevalence of cancer in COVID-19 patients, or providing data of cancer between patients with severe or non-severe illness or between non-survivors and survivors. Meta-analyses were performed to estimate the pooled prevalence and odds risk (OR) using the inverse variance method with the random-effects model. Results:Thirty-four studies with 8080 patients were included. The pooled prevalence of cancer in patients with COVID-19 was 2.0% (95% CI: 2.0% to 3.0%). The prevalence in Italy (5.0%), France (6.0%), and Korea (4.0%) were higher than that in China (2.0%). Cancer was associated with a 2.84-fold significantly increased risk of severe illness (OR = 2.84, 95%CI: 1.75 to 4.62, P < 0.001) and a 2.60-fold increased risk of death (OR = 2.60, 95%CI: 1.28 to 5.26, P = 0.008) in patients with COVID-19.Sensitivity analyses showed that the results were stable after excluding studies with a sample size of less than 100. : medRxiv preprint 3 associated with a significantly increased risk of severity and mortality of patients with COVID-19.

show abstract

Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis

Cited by 576 publications

References 42 publications

COVID-19 and Cancer: A Comparative Case Series

COVID-19 and Cancer: A Comparative Case Series

Clinical Features and Outcomes of COVID-19 in Older Adults: A Systematic Review and Meta-Analysis

Cancer is associated with the severity and mortality of patients with COVID-19: a systematic review and meta-analysis

Contact Info

Product

Resources

About